secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001999371-25-020361
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix licenses exclusive worldwide rights to TNX-4900 for neuropathic pain from Rutgers University
--------------------------------------------------------------------------------

- Licensed exclusive worldwide rights to TNX-4900 (S1R antagonist) from Rutgers University for chronic neuropathic pain.
- TNX-4900: Ki=7.5 nM, >100-fold selectivity over Sigma-2, oral bioavailability ~28%.
- Preclinical efficacy in diabetic and chemotherapy-induced neuropathic pain models without tolerance or motor impairment.
- Company plans IND-enabling studies; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125020361/0001999371-25-020361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125020361/tonix-8k_121625.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-020361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer